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Abbreviations 
 
AV = atrioventricular  
CI = 95% confidence interval  
CRT-D = cardiac resynchronization therapy defibrillator 
CRT-P = cardiac resynchronization therapy pacemaker 
DCM = dilated cardiomyopathy 
ECG = electrocardiogram 
EP = electrophysiologic  
ESC = European Society of Cardiology 
EU = European Union  
EU-CERT-ICD = EUropean Comparative Effectiveness Research to Assess the Use of Primary ProphylacTic 
Implantable Cardioverter Defibrillators 
GCP = Good Clinical Practice  
HR = hazard ratio 
ICD = implantable cardioverter defibrillator  
ICM = ischemic cardiomyopathy  
LVEF = left ventricular ejection fraction  
NYHA = New York Heart Association 
QoL = quality of life 
SCD = sudden cardiac death 
SPRM = Seattle Proportional Risk Model 
US = United States 
VA = Veterans Administration 
 
 
 
Journal Pre-proof
Jo
urn
al 
Pr
e-p
roo
f
 
 
4 
 
 
Abstract 
 
Background. The clinical effectiveness of primary prevention implantable cardioverter defibrillator (ICD) 
therapy is under debate. It is urgently needed to better identify patients who benefit from prophylactic ICD 
therapy. The EUropean Comparative Effectiveness Research to Assess the Use of Primary ProphylacTic 
Implantable Cardioverter Defibrillators (EU-CERT-ICD) completed in 2019 will assess this issue. 
Summary. The EU-CERT-ICD is a prospective investigator-initiated non-randomized, controlled, multicenter 
observational cohort study done in 44 centers across 15 European countries. A total of 2327 patients with 
heart failure due to ischemic heart disease or dilated cardiomyopathy indicated for primary prophylactic ICD 
implantation were recruited between 2014 and 2018 (>1500 patients at first ICD implantation, >750 patients 
non-randomized non-ICD control group). The primary endpoint was all-cause mortality, first appropriate shock 
was co-primary endpoint. At baseline, all patients underwent 12-lead ECG and Holter-ECG analysis using 
multiple advanced methods for risk stratification as well as documentation of clinical characteristics and 
laboratory values. The EU-CERT-ICD data will provide much needed information on the survival benefit of 
preventive ICD therapy and expand on previous prospective risk stratification studies which showed very good 
applicability of clinical parameters and advanced risk stratifiers in order to define patient subgroups with above 
or below average ICD benefit.   
Conclusion. The EU-CERT-ICD study will provide new and current data about effectiveness of primary 
prophylactic ICD implantation. The study also aims for improved risk stratification and patient selection using 
clinical risk markers in general, and advanced ECG risk markers in particular. 
 
Keywords: implantable cardioverter defibrillator; risk factors; mortality; sudden cardiac death 
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Introduction  
Multicenter landmark trials have long established that implantable cardioverter-defibrillator (ICD) therapy is 
useful for primary prevention of sudden cardiac death (SCD)(1, 2). After guideline implementation, ICDs quickly 
became routine treatment. Almost two decades later, outcome events have noticeably decreased(3) and non-
sudden modes of death compete with the occurrence of malignant arrhythmias and SCD so that many ICD 
patients never receive appropriate shocks(4). Important sub-groups, such as patients with more advanced 
heart failure(2, 5), with advanced kidney disease(6), women(7), or diabetics(8) may have an ICD benefit below 
average. The overall negative results of the DANISH-ICD trial(9) highlighted this dilemma and prompted further 
debate. DANISH showed that ICD therapy currently does not reduce mortality in all patients with non-ischemic 
cardiomyopathy. From the original DANISH data, it was shown that increasing age is associated with loss of ICD 
survival benefit(10), i.e. that age should be an important determinant of ICD indication. Better diagnostic 
criteria for indicating prophylactic ICD therapy are urgently needed to ensure the expected survival benefit 
from device therapy to the patient.  
 
Considerations on ICD survival benefit 
Clinical risk scores to predict all-cause mortality in ICD candidates are ready to use with high accuracy and 
reproducibility(11). The incidence of malignant arrhythmias and appropriate ICD shocks is not proportional to 
overall mortality(5, 12) (see Figures 1, 2), therefore risk of arrhythmic death can vary greatly among patients 
with reduced left ventricular ejection fraction (LVEF). ICD survival benefit can be estimated by the relative 
magnitudes of malignant arrhythmia risk versus overall mortality risk(12-14), first demonstrated by Goldenberg 
et al(13) and Levy et al(14) (see Figures 1,3, adapted from (5). Unfortunately, specific prediction of malignant 
ventricular arrhythmias, i.e. also SCD, is more difficult and requires different predictor variables(5, 12), for 
instance electrophysiologic (EP) stimulation. ICDs reliably abort SCD caused by ventricular tachycardia and 
ventricular fibrillation, so prediction of arrhythmic risk is critical to identify patients with positive ICD benefit. 
Using simultaneous prediction of expected mortality risk and appropriate shock, individual ICD benefits can be 
estimated (see Figures 1,3, adapted from(5)). Patients with very high mortality may not derive ICD benefit 
because of a higher proportion of non-sudden and non-cardiac death risk(4, 5, 12-14)(see Figures 1-3). If higher 
shock risk coincides with lower mortality risk, ICD survival benefit will be particularly high. As shown in Figure 
3B (yellow curve), 20% of the patients in the EUTrigTreat clinical study (the upper quintile of the shock score) 
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6 
featured a ≈10% annual risk of appropriate shock, therefore they undoubtedly derive a high survival benefit 
from their device(5). There is a lower end of risk where event probabilities are too low for the defibrillator to 
exert benefit(13). In other circumstances of SCD risk, a <1% annual risk of SCD has been discussed as not 
sufficiently high for ICD prophylaxis.  From the EUTrigTreat prospective cohort(5), a considerable number of 
ICD patients can be identified with low shock probability and low mortality, i.e. a low chance of benefit (Figures 
1,3). We also found that 20% of patients in the EUTrigTreat study(5) featured a high all-cause mortality of ≈11% 
annually (Figure 3A: yellow curve). One cannot be exactly sure whether the high mortality in this subgroup 
confers a reasonable proportion of arrhythmic deaths which would make ICD therapy very useful or whether 
there is rather a high proportion of non-arrhythmic deaths among these patients limiting its use. This is where 
separate prediction of arrhythmic deaths and non-sudden deaths is urgently needed. EP testing is an excellent 
diagnostic test to predict arrhythmic risk(5), for practical reasons an ECG parameter with similar predictive 
capability would be highly desirable. Altogether, the scoring system derived from the data of Bergau et al (5) 
shows a good discrimination between low, moderate and high risks for appropriate shocks and all-cause 
mortality as indicated by C-statistics between 0.69 (shocks) and 0.86 (mortality). A similar grading system, a 
bimodal survival and implantable defibrillator (BaSIS) risk model was developed and proposed by the Ontario 
ICD registry group and Lee et al(15). In this paper, a meticulous collection of clinical information in 3445 
patients undergoing ICD implantation accurately allowed to grade the two outcomes shock and death in these 
patients. The cohort was divided into risk deciles with very large differences in the risks of mortality (36-fold 
from first to tenth decile) and appropriate shock (8-fold from first to tenth decile). No additional diagnostic 
testing for risk stratification was undertaken as the basis for the study was a registry collection of data.  In this 
respect, appropriate shock risk can be replaced by the proportional risk of sudden cardiac death which is the 
principle of the Seattle Proportional Risk Model (SPRM)(12). As a recent example, Kristensen et al measured 
the SPRM from the original DANISH study(16). In 1116 patients, the authors could show that 558 patients with 
an SPRM above the median had much better risk reduction by ICD therapy (HR 0.63, 95% CI 0.43 – 0.94) than 
558 patients with SPRM below the median (HR 1.08, 95% CI 0.78 – 1.49, p for interaction = 0.04).  
 
 
Importance of age-specific ICD treatment effect 
The recent DANISH-ICD trial also showed that elderly patients with non-ischemic cardiomyopathy and an LVEF 
≤ 35% did not derive a survival benefit from ICD treatment(9). In a post-hoc analysis from the DANISH study, 
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age was demonstrated as an important factor connected to ICD benefit. ICD survival benefit was significant in 
patients younger than 70 years but was lost in elderly patients. The interaction p-value was 0.009 for age 
divided into tertiles which is a remarkable value for clinical studies of this size and duration(10). Harm could be 
suspected in patients above 80 years. These results are in contrast with meta-analytic data from older ICD 
landmark studies where a decline of ICD benefit with age was also shown(17), but patients up to an age of 90 
years had a persistent survival benefit from ICD treatment. Cardiovascular treatments and outcomes may have 
widely changed between the two eras. From the Ontario ICD registry, Yung et al(18) had shown in 5399 
patients that mortality increases with age but rates of appropriate shocks remain similar between all age 
groups. Sponsored by the US Veterans Administration the I-70 study (NCT 02121158) currently randomizes 
1000 elderly patients ≥ 70 years to a primary prophylactic ICD vs. control without ICD.  
 
 
Rationale of European ICD studies 
The findings by Goldenberg et al(13) and Levy et al(14) were hypothesis-generating for the prospective 
EUTrigTreat(5, 19)(2009-2015) and EU-CERT-ICD studies(20)(2013-2018) which searched for the best 
combination of EP risk stratification tests and clinical parameters to predict competing risks of ICD shocks 
versus mortality and guide the selection for prophylactic ICD treatment. We hypothesized subgroups with high 
competing non-sudden or non-cardiac mortality as well as defined patients with a higher risk of malignant 
arrhythmias. In the EUTrigTreat clinical study, Bergau et al(5) showed that all-cause mortality risk and 
appropriate shock risk could be very accurately predicted in 672 ICD patients with primary prophylactic and 
secondary prophylactic indications (Figures 1-3). When designing the EU-CERT-ICD “EUropean Comparative 
Effectiveness Research to assess the use of primary prophylacTic Implantable Cardioverter Defibrillators (EU-
CERT-ICD)” prospective study in 2012, a randomized trial did not seem ethically appropriate due to the wide 
implementation of ICD therapy and unequivocal guidelines. We therefore set out to design a large prospective 
study establishing a non-randomized control group without ICDs as feasible. 
 
The EU-CERT-ICD project – general concept  
In general, we made use of disparities of ICD implant rates across Europe(21). Several of the participating 
centers and countries did not have access to primary prophylactic implantation due to lack of reimbursement 
in some or all of their patients, these centers eventually recruited about 60% of the non-ICD control patients. 
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Furthermore, there were control patients that had refused a recommended primary prevention ICD 
implantation on personal preference. The study was funded by the European Community's Seventh Framework 
Programme (FP7). A central prospective study(20), a retrospective registry(7) and meta-analyses in primary 
prophylactic ICD patients were set up(22, 23). Over the course of the project so far, several original papers and 
editorials have been published from the various work packages (see www.eu-cert-icd.eu). Primary objectives of 
the project were 1) to characterize all-cause mortality in a prospective controlled non-randomized study of ICD 
candidates for primary prophylaxis of SCD, and compare newly implanted ICD patients with a non-randomized 
control group without ICD treatment; 2) to determine the contribution of prespecified clinical baseline 
characteristics to the risk of the primary outcomes; 3) to define subgroups within the ICD primary prevention 
guideline cohort with a lower or higher benefit from ICD treatment; 4) t  assess simple and cost-effective 
electrocardiographic noninvasive risk stratification techniques; 5) to identify predictors for appropriate shocks 
using ECG-related parameters and autonomic parameters, and to characterize subgroups with a deviating risk 
for appropriate shock, in particular focusing on the role of sex category; 7) to biobank a genetic blood sample 
from each patient; 8) to provide outcome data for health economic evaluation of ICD use including quality of 
life (QoL) with particular focus to subgroups and country-specific differences;  
 
EU-CERT-ICD: Prospective study design and protocol 
The EU-CERT-ICD prospective trial (www.clinicaltrials.gov, NCT02064192) is an investigator-initiated non-
randomized, open, controlled, observational multicenter study(20) in 2250 analyzable patients with ischemic or 
dilated cardiomyopathy that were candidates for a primary prevention ICD by current guidelines. In the ICD 
treatment group, 1500 analyzable patients at first ICD implantation were targeted. A non-randomized control 
group of 750 patients without ICDs was recruited to generate contemporary comparative data on ICD survival 
benefit. To achieve this, 2327 patients were targeted. Inclusion and exclusion criteria are shown in Table 1. 
Sample size calculations were done in order to compare ICD patients with controls regarding mortality, and for 
stratification of the ICD cohort for appropriate shocks and mortality. Estimated from previous studies, an 
annualized mortality of 4.5% and a first appropriate ICD shock rate of 4.5% were expected. For a power of 80% 
at a two-sided significance level of 5%, in a 4-year study a sample of 1500 ICD patients and 750 controls was 
calculated to generate at least 279 death events(20). For independent binary or dichotomized risk stratifiers to 
provide hazard ratios of about 2 between a high and a low risk group we calculated that 122 deaths yielded 
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95% power for a two-sided significance level of 5%. Correspondingly, 108 appropriate ICD shocks were 
required if the ratio of high and low risk group sizes was 1:1 and an annual appropriate ICD shock rate of about 
4.5% was observed. Predefined subgroups were the elderly, diabetics, women and patients with comorbidities 
with a higher likelihood of non-arrhythmic death as also identified from the mortality score. Reasons for non-
ICD status had to be unrelated to the study. Balancing of clinical characteristics between ICD and control 
groups was approached using multivariate analyses and propensity score methods. Primary endpoint was all-
cause mortality, first appropriate shock was a co-primary endpoint in ICD patients. Secondary endpoints of the 
study included SCD, non-cardiac mortality, first inappropriate shock.  A 12-lead Holter ECG (Getemed, 
Teltow/Germany) was recorded at 1kHz for 24 hours at baseline and analyzed for all standard ECG parameters, 
short-term advanced parameters, and advanced Holter ECG parameters (Table 2). The number of patients with 
atrial fibrillation was limited to 15%. A large number of clinical baseline parameters were documented at 
enrollment of each patient(20).  ICD patients were followed every 3 to 6 months or remotely. Patients in the 
non-ICD control group were scheduled every 6 to 12 months according to clinical needs. Mandatory 
programming called for rate cutoffs at 200 and 240 bpm, programming changes were recorded. Outcome 
information was retrieved by phone and mail from patients, relatives, general practitioners, hospital records, 
or local authorities. Deaths were classified as SCD, cardiac, or non-cardiac. ICD shocks were adjudicated as 
appropriate or inappropriate. Crossover of patients from the control group to the ICD group was allowed at the 
discretion of the treating physicians, and occurred in ≈ 4% of patients who remained in the study. QoL was 
assessed at baseline and annually (SF-36, MacNew, Florida Patient Acceptance Survey). Validated health 
economics questionnaires were collected in Germany and Switzerland to assess true health care costs. QoL-
adjusted cost-effectiveness is estimated from cost comparisons and Markov models. A combination of central 
monitoring and on-site monitoring was chosen to ensure data completeness, data quality and study conduct in 
accordance with the protocol and GCP guidelines. Cox proportional hazards regression analyses or Fine & Gray 
proportional sub-distribution hazard regression analyses are performed to quantify the predictive value of 
multiple categorical variables and dichotomized continuous variables.  
 
Other ICD studies with potential to change ICD indications 
The DO-IT registry study funded by Dutch health insurers will report outcomes including cost-effectiveness 
from 1500 primary prophylactic ICD patients with LVEF ≤ 35% from the Netherlands (24). The randomized 
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RESET-CRT trial (NCT03494933) is funded by the German health system and randomizes 2000 heart failure 
patients with an LVEF ≤ 35% and QRS ≥ 150 ms between CRT-D and CRT-P.  The I-70 study sponsored by the VA 
(NCT 02121158) randomizes 1000 elderly patients >= 70 years to a primary prophylactic ICD vs. control without 
ICD. A number of studies are underway to evaluate risk stratification of ICM patients with LVEF between 36% 
and 50%. Overall average risk is smaller in this group, not excluding that selected patients have a high risk of 
SCD and may be good candidates for ICD treatment. These are REFINE-ICD (NCT00673842) using T-wave 
alternans and heart-rate turbulence, SMART-MI (NCT02594488) using periodic repolarization dynamics(25), 
PRESERVE EF (NCT02124018) using programmed ventricular stimulation, and CMR-Guide (NCT01918215) using 
magnetic resonance imaging.   
 
Summary and conclusions 
Appropriate identification of patient subgroups with significant mortality benefit from ICD therapy remains 
critical, and incorporation of variables beyond LVEF and NYHA functional class is warranted. It is almost certain 
that not all patients identified by LVEF ≤ 35% have survival benefit from ICD therapy. The EU-CERT-ICD study 
results upcoming in 2019 will provide contemporary data on effectiveness of primary prophylactic ICD 
implantation in ICM and DCM. Using multivariable regression statistics of the primary endpoint, we will 
calculate an adequately powered hazard ratio of the ICD survival effect (as the primary measure of ICD benefit) 
in the overall cohort and predefined subgroups. Risk scores for mortality and shock will be provided building on 
a large number of useful parameters, e.g. ECG markers, cardiovascular history, biomarkers, and possible 
combinations thereof. The results will permit assessment of the predictive value of several state-of-the-art 
advanced ECG methods for application in clinical decision-making. Facing a risk continuum of arrhythmic risk 
and SCD risk which has a wide range of proportions to all-cause mortality and cardiac mortality, patient 
decisions should be individualized and currently based on simple parameters such as age, NYHA, BNP, atrial 
fibrillation, creatinine, the existence of comorbidities, possibly adjunct diagnostic tests such as EP stimulation 
and magnetic resonance imaging may be used.  
 
 
FUNDING 
The research leading to the results has received funding from the European Community's Seventh Framework 
Programme FP7/2007–2013 under grant agreement No. HEALTH-F2-2009-241526, EUTrigTreat, and grant 
Journal Pre-proof
Jo
urn
al 
Pr
e-p
roo
f
 
 
11 
agreement No. HEALTH-F2-2009-602299, EU-CERT-ICD. G.H. and T.F. are principle investigators of the German 
Center for Cardiovascular Research (DZHK), partner site Göttingen. R.W. is supported as a postdoctoral clinical 
researcher by the Fund for Scientific Research Flanders (FWO). 
 
Conflicts of Interest 
none declared  
 
References 
1. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, et al. Prophylactic implantation 
of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 
2002;346(12):877-83. 
2. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, et al. Amiodarone or an 
implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352(3):225-37. 
3. Shen L, Jhund PS, Petrie MC, Claggett BL, Barlera S, Cleland JGF, et al. Declining Risk of 
Sudden Death in Heart Failure. N Engl J Med. 2017;377(1):41-51. 
4. Koller MT, Schaer B, Wolbers M, Sticherling C, Bucher HC, Osswald S. Death without prior 
appropriate implantable cardioverter-defibrillator therapy: a competing risk study. Circulation. 
2008;117(15):1918-26. 
5. Bergau L, Willems R, Sprenkeler DJ, Fischer TH, Flevari P, Hasenfuss G, et al. Differential 
multivariable risk prediction of appropriate shock versus competing mortality - A prospective cohort 
study to estimate benefits from ICD therapy. Int J Cardiol. 2018;272:102-7. 
6. Jukema JW, Timal RJ, Rotmans JI, Hensen LCR, Buiten MS, de Bie MK, et al. Prophylactic 
Use of Implantable Cardioverter-Defibrillators in the Prevention of Sudden Cardiac Death in Dialysis 
Patients. Circulation. 2019;139(23):2628-38. 
7. Sticherling C, Arendacka B, Svendsen JH, Wijers S, Friede T, Stockinger J, et al. Sex 
differences in outcomes of primary prevention implantable cardioverter-defibrillator therapy: combined 
registry data from eleven European countries. Europace. 2018;20(6):963-70. 
8. Junttila J, Huikuri H, Pelli A, Ke ttä T, Friede T, Willems R, et al. Appropriate shocks and 
mortality in diabetic and vs. non-diabetic patients with prophylactic implantable cardioverter-
defibrillator. Heart rhythm : the official journal of the Heart Rhythm Society. 2018;15(5):S300. 
9. Kober L, Thune JJ, Nielsen JC, Haarbo J, Videbaek L, Korup E, et al. Defibrillator Implantation 
in Patients with Nonischemic Systolic Heart Failure. N Engl J Med. 2016;375(13):1221-30. 
10. Elming MB, Nielsen JC, Haarbo J, Videbaek L, Korup E, Signorovitch J, et al. Age and 
Outcomes of Primary Prevention Implantable Cardioverter-Defibrillators in Patients With Nonischemic 
Systolic Heart Failure. Circulation. 2017;136(19):1772-80. 
11. Bilchick KC, Stukenborg GJ, Kamath S, Cheng A. Prediction of mortality in clinical practice for 
medicare patients undergoing defibrillator implantation for primary prevention of sudden cardiac death. 
J Am Coll Cardiol. 2012;60(17):1647-55. 
12. Bilchick KC, Wang Y, Cheng A, Curtis JP, Dharmarajan K, Stukenborg GJ, et al. Seattle Heart 
Failure and Proportional Risk Models Predict Benefit From Implantable Cardioverter-Defibrillators. J 
Am Coll Cardiol. 2017;69(21):2606-18. 
13. Goldenberg I, Vyas AK, Hall WJ, Moss AJ, Wang H, He H, et al. Risk stratification for primary 
implantation of a cardioverter-defibrillator in patients with ischemic left ventricular dysfunction. J Am 
Coll Cardiol. 2008;51(3):288-96. 
14. Levy WC, Lee KL, Hellkamp AS, Poole JE, Mozaffarian D, Linker DT, et al. Maximizing 
survival benefit with primary prevention implantable cardioverter-defibrillator therapy in a heart failure 
population. Circulation. 2009;120(10):835-42. 
15. Lee DS, Hardy J, Yee R, Healey JS, Birnie D, Simpson CS, et al. Clinical Risk Stratification for 
Primary Prevention Implantable Cardioverter Defibrillators. Circulation Heart failure. 2015;8(5):927-37. 
16. Kristensen SL, Levy WC, Shadman R, Nielsen JC, Haarbo J, Videbaek L, et al. Risk Models 
for Prediction of Implantable Cardioverter-Defibrillator Benefit: Insights From the DANISH Trial. JACC 
Heart Fail. 2019;7(8):717-24. 
Journal Pre-proof
Jo
urn
al 
Pr
e-p
roo
f
 
 
12 
17. Hess PL, Al-Khatib SM, Han JY, Edwards R, Bardy GH, Bigger JT, et al. Survival benefit of 
the primary prevention implantable cardioverter-defibrillator among older patients: does age matter? 
An analysis of pooled data from 5 clinical trials. Circulation Cardiovascular quality and outcomes. 
2015;8(2):179-86. 
18. Yung D, Birnie D, Dorian P, Healey JS, Simpson CS, Crystal E, et al. Survival after 
implantable cardioverter-defibrillator implantation in the elderly. Circulation. 2013;127(24):2383-92. 
19. Seegers J, Vos MA, Flevari P, Willems R, Sohns C, Vollmann D, et al. Rationale, objectives, 
and design of the EUTrigTreat clinical study: a prospective observational study for arrhythmia risk 
stratification and assessment of interrelationships among repolarization markers and genotype. 
Europace. 2012;14(3):416-22. 
20. Zabel M, Sticherling C, Willems R, Lubinski A, Bauer A, Bergau L, et al. Rationale and design 
of the EU-CERT-ICD prospective study: comparative effectiveness of prophylactic ICD implantation. 
ESC Heart Fail. 2019;6(1):182-93. 
21. Raatikainen MJ, Arnar DO, Merkely B, Camm AJ, Hindricks G. Access to and clinical use of 
cardiac implantable electronic devices and interventional electrophysiological procedures in the 
European Society of Cardiology Countries: 2016 Report from the European Heart Rhythm 
Association. Europace. 2016;18 Suppl 3:iii1-iii79. 
22. Conen D, Arendacka B, Rover C, Bergau L, Munoz P, Wijers S, et al. Gender Differences in 
Appropriate Shocks and Mortality among Patients with Primary Prophylactic Implantable Cardioverter-
Defibrillators: Systematic Review and Meta-Analysis. PloS one. 2016;11(9):e0162756. 
23. Bergau L, Tichelbacker T, Kessel B, Luthje L, Fischer TH, Friede T, et al. Predictors of 
mortality and ICD shock therapy in primary prophylactic ICD patients-A systematic review and meta-
analysis. PloS one. 2017;12(10):e0186387. 
24. van Barreveld M, Dijkgraaf MGW, Hulleman M, Boersma LVA, Delnoy P, Meine M, et al. 
Dutch outcome in implantable cardioverter-defibrillator therapy (DO-IT): registry design and baseline 
characteristics of a prospective observational cohort study to predict appropriate indication for 
implantable cardioverter-defibrillator. Netherlands heart journal : monthly journal of the Netherlands 
Society of Cardiology and the Netherlands Heart Foundation. 2017;25(10):574-80. 
25. Rizas KD, McNitt S, Hamm W, Massberg S, Kaab S, Zareba W, et al. Prediction of sudden 
and non-sudden cardiac death in post-infarction patients with reduced left ventricular ejection fraction 
by periodic repolarization dynamics: MADIT-II substudy. Eur Heart J. 2017;38(27):2110-8. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Journal Pre-proof
Jo
urn
al 
Pr
e-p
roo
f
 
 
13 
 
 
Figure legends 
 
Figure 1: Distribution of patients to combinations of risk categories (low, intermediate, high) and their  
associated annualized mortality and shock risks (modified from reference (5) (EUTrigTreat clinical study), 
with permission) Grey circles denote the frequencies of patients in the various categories. The red and blue 
bars denote the actual annualized shock and mortality risks in a category, respectively. For each risk, the cohort 
is divided into three risk groups (low:  two quintiles, intermediate: two quintiles, high: one quintile), resulting in 
nine subgroups, of which seven have significant size. Annualized shock risk is found to be >10% per year in the 
highest quintile of the shock score and coincides with both an intermediate (4.4% per year) and a high (10.2% 
per year) mortality. Annualized mortality risk is found to be >10% per year in the highest quintile of the 
mortality score and coincides with both an intermediate (5.1% per year) and a high risk of appropriate shock. 
 
 
Figure 2: Correlation scatter plot for calculated risk score values of appropriate shock vs. calculated risk score 
value for mortality (r = 0.56, p < 0.001) (modified from reference (5) (EUTrigTreat clinical study), with 
permission) 
 
Horizontal and vertical lines depict the low, intermediate, and high-risk values of each score. The figure shows 
that the correlation is at best moderate despite statistical significance. Thus, all-cause mortality risk does not 
coincide well with appropriate shock risk. Horizontal and vertical lines show the classification of risk scores into 
low/intermediate/high categories. Individually, a low risk of appropriate shock does occur with a high 
competing risk of death limiting the effectiveness of implantable cardioverter defibrillator therapy in a given 
patient (lower right quadrant). Vice versa, individual patients can be identified with fairly high risks of 
appropriate shock and concomitant moderate risks of death (upper left quadrant). These individuals are 
expected to have a higher life-prolonging effect of their implantable cardioverter defibrillator therapy, i.e. 
higher implantable cardioverter defibrillator benefit.  
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Figure 3: Differentiation of arrhythmia risk and all-cause mortality risk in ICD patients (modified from 
reference (5) (EUTrigTreat clinical study), with permission) 
Cumulative event-probability curves for mortality and appropriate shock (Panel A and B). For each risk, the 
cohort is divided into three risk groups (low: two quintiles, intermediate: two quintiles, high: one quintile), the 
calculation is provided by separate risk scores for all-cause mortality and appropriate shock. The dashed lines 
indicate the cumulative event-probabilities after bootstrap bias correction.  
 
Panel A: The mortality risk score provides excellent separation of low, intermediate, and high mortality risks. 
The low risk mortality group (two quintiles) shows an annualized risk of 0.5%. In contrast, the high-risk 
mortality group (one quintile) features an annual risk of 11%. Within the latter patients, it can be expected that 
non-sudden cardiac deaths or noncardiac deaths compete with the occurrence of ventricular arrhythmias. 
Patients with a low predicted shock risk may not improve their prognosis wearing an ICD.  
Panel B: The appropriate shock risk score provides good separation of low, intermediate, and high shock risks. 
The low risk shock group, a large group covering two quintiles (40% of patients in the cohort) has an average 
annual risk of 1.8%. Since a first appropriate shock corresponds with a potential SCD in 30–50%, this number 
corresponds to an SCD rate < 1%/year. In patients with an estimated SCD rate < 1% annually, depending on age 
and other mortality factors independent of arrhythmias, omission of an ICD may be discussed. In contrast, the 
high-risk group for shock (one quintile) features an average annual risk of ≈8.5%, qualifying the patient for an 
ICD with high survival benefit. In the intermediate risk of shock group (two quintiles), the risk is still ≈4% 
annually, corresponding to possibly a 2% annual SCD rate in a parallel non-ICD group. Patients in the 
intermediate risk group for shock should probably also obtain an ICD as they derive ICD benefit unless a very 
high competing risk 
of non-arrhythmic mortality can be seen from the mortality score 
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Tables  
 
Table 1: Inclusion and Exclusion Criteria of the EU-CERT-ICD prospective study (modified from Zabel et al(20) 
with permission (EU-CERT-ICD design publication) 
 
Inclusion Criteria  
 Ischemic or dilated cardiomyopathy, LVEF  35 % 
 NYHA (New York Heart Association) functional class II-III (or NYHA functional class I and LVEF 
≤ 30%) 
 Indication for primary prevention ICD treatment according to current European Society of 
Cardiology guidelines 
 Age  18 years 
 Written informed consent 
Exclusion criteria  
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 Secondary prophylactic ICD indication  
 Planned or indicated cardiac resynchronization therapy  
 Unstable cardiac condition  
 Higher degree AV-block  
 Previous pacemaker or device therapy  
 Life expectancy ≤ 1 year  
 
 
 
 
 
 
 
 
 
Table 2: Parameters to be analyzed in the EU-CERT-ICD prospective study from 12-lead 24-hour Holter 
recordings (modified from Zabel et al(20) with permission (EU-CERT-ICD design publication) 
 
24 hour – Holter parameters  
 Number of premature ventricular complexes 
 Number of episodes and rate of non-sustained ventricular tachycardia 
 Respiration triggered sinus arrhythmia 
 Modified moving average T-wave alternans 
 Periodic repolarization dynamics  
 Heart rate variability including standard deviation of RR intervals (SDNN), root mean square of 
successive differences in RR intervals 
 Frequency domain HRV parameters 
 Heart rate turbulence: turbulence onset, turbulence slope 
 Acceleration capacity 
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 Deceleration capacity 
 
Advanced short-term ECG parameters 
 T-peak-to-T-end interval 
 J-point elevation 
 Fractionation index 
 Early repolarization 
 Short-term variability of the QT interval 
 Total cosine R-to-T  
 Relative T-wave residuum  
 T-wave morphology dispersion  
 T-wave loop dispersion 
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